PT - JOURNAL ARTICLE AU - Alnoumas, Layla AU - van Den Driest, Lisa AU - Lannigan, Alison AU - Johnson, Caroline H AU - Rattray, Nicholas JW AU - Rattray, Zahra TI - The role of <em>KPNA2</em> mutations in breast cancer prognosis: A survey of publicly available databases AID - 10.1101/2021.11.10.21266193 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.10.21266193 4099 - http://medrxiv.org/content/early/2021/11/14/2021.11.10.21266193.short 4100 - http://medrxiv.org/content/early/2021/11/14/2021.11.10.21266193.full AB - Breast cancer, comprising of several sub-phenotypes, is a leading cause of female cancer-related mortality in the UK and accounts for 15% of all cancer cases. Chemoresistant sub phenotypes of breast cancer remain a particular challenge. However, the rapidly-growing availability of clinical datasets, presents the scope to underpin a data driven precision medicine-based approach exploring new targets for diagnostic and therapeutic interventions. We report a survey of several publicly available databases probing the expression and prognostic role of Karyopherin-2 alpha (KPNA2) in breast cancer prognosis. Aberrant KPNA2 overexpression is directly correlated with aggressive tumour phenotypes and poor patient survival outcomes. We examined the existing information available on a range of commonly occurring mutations of KPNA2 and their correlation with patient survival.Our analysis of clinical gene expression datasets show that KPNA2 is frequently amplified in breast cancer, with differences in expression levels observed as a function of patient age and clinicopathologic parameters. We also found that aberrant KPNA2 overexpression is directly correlated with poor patient prognosis, warranting further investigation of KPNA2 as an actionable target for patient stratification or the design of novel chemotherapy agents.In the era of big data, the wealth of datasets available in the public domain can be used to underpin proof of concept studies evaluating the biomolecular pathways implicated in chemotherapy resistance in breast cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding awarded to Zahra Rattray from Tenovus Scotland, The Royal Society of Edinburgh Research Reboot, FRAME summer studentship for LVD internship, and Kuwait University for LA PhD scholarship funding. We acknowledge support to Caroline Johnson from the American Cancer Society Research Scholar Grant 134273-RSG-20-065-01-TBE and the US National Cancer Institute of the National Institutes of Health under Award Number K12CA215110.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data have been obtained from open access sources such as cBioportal, Geneminer, Oncomine and KMPlot.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.